Paper197883
The low-density lipoprotein pathway and its relation to atherosclerosis.
Goldstein JL and 1 other. Annu Rev Biochem, 1977. Cited by 2,363 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. The low-density lipoprotein pathway and its relation to atherosclerosis. Papers, record 197883. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/197883
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Arteriosclerosis | Major topic |
| Lipoproteins, LDL | Major topic |
| Aorta | |
| Apolipoproteins | |
| Cholesterol | |
| Cholesterol Esters | |
| Endocytosis | |
| Fibroblasts | |
| Humans | |
| Intestinal Mucosa | |
| Kinetics | |
| Liver | |
| Models, Biological | |
| Molecular Weight | |
| Protein Binding | |
| Receptors, Drug |
Source PubMed
Cited by429
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2,363 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,852,022 | Rare Diseases as Engines of Biomedical Innovation: Lessons for Gene Therapy and Common Disease. | Yale J Biol Med | 2026 | https://conductscience.org/library/papers/42852022 | PubMed |
| 42,182,449 | Impaired lipoprotein secretion by APOE4 leads to lysosomal and mitochondrial dysfunction in human microglia. | bioRxiv | 2026 | https://conductscience.org/library/papers/42182449 | PubMed |
| 42,074,289 | Targeting the NLRP3 Inflammasome in Atherosclerosis: A Review of Natural Products and Their Molecular Mechanisms. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42074289 | PubMed |
| 41,964,074 | Sex- and age-dependent mitochondrial dysfunction and cognitive impairment in a mouse model of familial hypercholesterolemia. | Biol Sex Differ | 2026 | https://conductscience.org/library/papers/41964074 | PubMed |
| 40,813,253 | Low HDL-The Challenge. | Clin Med Res | 2025 | https://conductscience.org/library/papers/40813253 | PubMed |
| 40,362,498 | The Role of Ubiquitination on Macrophages in Cardiovascular Diseases and Targeted Treatment. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40362498 | PubMed |
| 39,966,374 | Energy metabolism in health and diseases. | Signal Transduct Target Ther | 2025 | https://conductscience.org/library/papers/39966374 | PubMed |
| 39,205,930 | Characterization of the daucosterol-lecithin complex and its impact on lipid metabolism in hyperlipidemic mice. | RSC Adv | 2024 | https://conductscience.org/library/papers/39205930 | PubMed |
| 38,974,714 | Gene editing therapy for cardiovascular diseases. | MedComm (2020) | 2024 | https://conductscience.org/library/papers/38974714 | PubMed |
| 38,892,201 | Discovering Inflammation in Atherosclerosis: Insights from Pathogenic Pathways to Clinical Practice. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38892201 | PubMed |
| 38,791,422 | Impact of CYP2C19 Gene Variants on Long-Term Treatment with Atorvastatin in Patients with Acute Coronary Syndromes. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38791422 | PubMed |
| 38,711,272 | Statins as anti-tumor agents: A paradigm for repurposed drugs. | Cancer Rep (Hoboken) | 2024 | https://conductscience.org/library/papers/38711272 | PubMed |
| 38,284,727 | Targeting Ferroptosis: A Novel Strategy for the Treatment of Atherosclerosis. | Mini Rev Med Chem | 2024 | https://conductscience.org/library/papers/38284727 | PubMed |
| 37,512,506 | The Role of Cholesterol in Chronic Lymphocytic Leukemia Development and Pathogenesis. | Metabolites | 2023 | https://conductscience.org/library/papers/37512506 | PubMed |
| 37,351,276 | Defining the ligand-dependent proximatome of the sigma 1 receptor. | Front Cell Dev Biol | 2023 | https://conductscience.org/library/papers/37351276 | PubMed |
| 37,154,584 | Total-, LDL-, and HDL-cholesterol, apolipoproteins, and triglycerides with risk of total and fatal prostate cancer in Black and White men in the ARIC study. | Prostate | 2023 | https://conductscience.org/library/papers/37154584 | PubMed |
| 36,876,496 | RNF130 Regulates LDLR Availability and Plasma LDL Cholesterol Levels. | Circ Res | 2023 | https://conductscience.org/library/papers/36876496 | PubMed |
| 36,235,012 | Polydatin: Pharmacological Mechanisms, Therapeutic Targets, Biological Activities, and Health Benefits. | Molecules | 2022 | https://conductscience.org/library/papers/36235012 | PubMed |
| 36,034,914 | The health effects of soy: A reference guide for health professionals. | Front Nutr | 2022 | https://conductscience.org/library/papers/36034914 | PubMed |
| 35,980,230 | Surface-modified nanotherapeutics targeting atherosclerosis. | Biomater Sci | 2022 | https://conductscience.org/library/papers/35980230 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/197883
GET https://conductscience.org/api/papers/v1/197883/cited_by?page=2